Consumer Rare-Subtype Oncology Clinical Trial Matcher
One-Liner
A patient-facing service taking a specific molecular cancer profile (from Foundation Medicine or Guardant NGS panel) and returning a ranked list of currently enrolling trials with eligibility flags and pre-populated referral packets
AI Thinking Process
Consumer Rare-Subtype Oncology Trial Match: patient-facing service taking specific molecular cancer profile and returning ranked enrolling trials for that exact subtype
Memory check: Antidote.me, TrialJectory, Massive Bio, CancerConnect, ResearchMatch, Deep 6 AI, Trial Hub, Leal Health, AACR JumpStart. Category is heavily populated.
KILLED: G035 consumer AI window firmly closed. Oncology trial matching is obvious use case, public data, strong motivation—occupied by multiple funded competitors. B2B pivot becomes a Deep 6 AI feature. G023 pivot fails.
Kill Reason
Consumer oncology trial matching is a fully occupied category with multiple well-funded competitors: Antidote.me, TrialJectory, Massive Bio, Leal Health, Deep 6 AI (B2B), CISCRP TrialReach—all using the same public ClinicalTrials.gov registry with no proprietary data or relationship advantage
Risk Analysis
Risk analysis available for latest engine ideas.
What do you think?
Related ideas you can explore free:
killed: Open-source middleware (HAMi) already provides heterogeneous AI computing virtualization for free. Proprietary play is squeezed between free open-source and vertically integrated hardware vendor ecosystem.
killed: 5+ funded competitors including Cast AI ($1B valuation), OneChronos (backed by Nobel laureate), Akash Network (decentralized, 80% cheaper), Argentum AI (blockchain-settled). Market is claimed with massive capital.
killed: Template epidemic (G003) + industry-pain-form death pattern (G005) fire simultaneously. 13+ existing compliance tools. A prompt could do 80% of this.